Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorDooley, Mary Anne
Ginzler, Ellen M
Olsen, Nancy J
Appel, Gerald B
Journal titleThe New England journal of medicine
Publication Begin page1886
Publication End page95
MetadataShow full item record
AbstractMaintenance therapy, often with azathioprine or mycophenolate mofetil, is required to consolidate remission and prevent relapse after the initial control of lupus nephritis.
We carried out a 36-month, randomized, double-blind, double-dummy, phase 3 study comparing oral mycophenolate mofetil (2 g per day) and oral azathioprine (2 mg per kilogram of body weight per day), plus placebo in each group, in patients who met response criteria during a 6-month induction trial. The study group underwent repeat randomization in a 1:1 ratio. Up to 10 mg of prednisone per day or its equivalent was permitted. The primary efficacy end point was the time to treatment failure, which was defined as death, end-stage renal disease, doubling of the serum creatinine level, renal flare, or rescue therapy for lupus nephritis. Secondary assessments included the time to the individual components of treatment failure and adverse events.
A total of 227 patients were randomly assigned to maintenance treatment (116 to mycophenolate mofetil and 111 to azathioprine). Mycophenolate mofetil was superior to azathioprine with respect to the primary end point, time to treatment failure (hazard ratio, 0.44; 95% confidence interval, 0.25 to 0.77; P = 0.003), and with respect to time to renal flare and time to rescue therapy (hazard ratio, <1.00; P < 0.05). Observed rates of treatment failure were 16.4% (19 of 116 patients) in the mycophenolate mofetil group and 32.4% (36 of 111) in the azathioprine group. Adverse events, most commonly minor infections and gastrointestinal disorders, occurred in more than 95% of the patients in both groups (P = 0.68). Serious adverse events occurred in 33.3% of patients in the azathioprine group and in 23.5% of those in the mycophenolate mofetil group (P = 0.11), and the rate of withdrawal due to adverse events was higher with azathioprine than with mycophenolate mofetil (39.6% vs. 25.2%, P = 0.02).
Mycophenolate mofetil was superior to azathioprine in maintaining a renal response to treatment and in preventing relapse in patients with lupus nephritis who had a response to induction therapy. (Funded by Vifor Pharma [formerly Aspreva]; ALMS ClinicalTrials.gov number, NCT00377637.).
CitationDooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N; ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011 Nov 17;365(20):1886-95. doi: 10.1056/NEJMoa1014460. PMID: 22087680.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International
- Sequential therapies for proliferative lupus nephritis.
- Authors: Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D
- Issue date: 2004 Mar 4
- Renal flare prediction and prognosis in lupus nephritis Hispanic patients.
- Authors: Mejía-Vilet JM, Córdova-Sánchez BM, Arreola-Guerra JM, Morales-Buenrostro LE, Uribe-Uribe NO, Correa-Rotter R
- Issue date: 2016 Mar
- Mycophenolate mofetil versus azathioprine as maintenance therapy for lupus nephritis: a meta-analysis.
- Authors: Feng L, Deng J, Huo DM, Wu QY, Liao YH
- Issue date: 2013 Feb
- Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.
- Authors: Mok CC, Ying KY, Yim CW, Siu YP, Tong KH, To CH, Ng WL
- Issue date: 2016 Jan
- Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis.
- Authors: Sahin GM, Sahin S, Kiziltas S, Masatlioglu S, Oguz F, Ergin H
- Issue date: 2008